Nico Löchner retweeted
German Federal Government invests 300 Million Euros in CureVac tinyurl.com/y7kxpqe4
$FGEN Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia in Non-Dialysis-Dependent Adult Patients with Chronic Kidney Disease prnewswire.com/news-releases…
$STML MENARINI GROUP TO ACQUIRE STEMLINE THERAPEUTICS
TOTAL POTENTIAL CONSIDERATION OF $12.50 PER SHARE COMPRISING $11.50 CASH AND $1.00 CONTINGENT VALUE RIGHT
$AFMD Affimed Mourns Passing of Chief Financial Officer Dr. Florian Fischer
affimed.com/affimed-mourns-p…
$AFMD Affimed Announces Appointment of Andreas Harstrick, M.D., as Chief Medical Officer
$FGEN PR
FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease
globenewswire.com/news-relea…
$FGEN
-In non dialysis-dependent patients receiving roxadustat, the risk of MACE, MACE+ and all-cause mortality was comparable to placebo
$FGEN
-Dialysis-dependent patients receiving roxadustat had a lower risk of MACE+ and no increased risk of MACE or all-cause mortality versus epoetin alfa
$FGEN
-In incident dialysis patients, roxadustat had a lower risk of MACE and MACE+ and showed a trend towards lower risk of all-cause mortality relative to epoetin alfa
$FGEN Roxadustat Phase III Program Pooled Analyses Showed Positive Efficacy and No Increased Cardiovascular Risk in Patients with Anemia from Chronic Kidney Disease Versus Comparators businesswire.com/news/home/2…
$MDCO ORION-11 STUDY MET ALL PRIMARY AND SECONDARY EFFICACY ENDPOINTS WITH EFFICACY CONSISTENT WITH PHASE 1 AND 2 STUDIES
Nico Löchner retweeted
$AFMD Investigating Safety And Preliminary Efficacy Of Afm13 Plus Pembrolizumab In Patients With Relapsed/Refractory Hodgkin Lymphoma After Brentuximab Vedotin Failure Https://onlinelibrary.wiley.…
$FGEN $AZN roxadustat
Q2'19 anaemia of CKD: data readout (pooled safety)
H2'19: anaemia of CKD: regulatory submission (US)
2020: anaemia of myelodysplastic syndrome: data readout
astrazeneca.com/content/dam/…
$HSGX Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics
$ALNY Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases